Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models
August 12, 2024 09:02 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Treatment with ZbtbB46 mRNA nanoparticles based on Altamira’s SemaPhore™ delivery technology results in significant reduction in...